What is Xencor?
Xencor, Inc. operates at the intersection of advanced protein engineering and therapeutic development. The company specializes in the discovery and advancement of engineered antibody and protein therapeutics, targeting a diverse range of serious medical conditions such as inflammatory diseases and oncology. By leveraging its proprietary technology, Xencor creates innovative biologic medicines that offer enhanced therapeutic profiles compared to traditional treatments. Its market position is defined by a focus on high-value partnerships and a deep pipeline of clinical-stage assets, establishing it as a critical entity in the biotechnology ecosystem.
How much funding has Xencor raised?
Xencor has raised a total of $237.2M across 7 funding rounds:
Series B
$12.3M
Series C
$50M
Series D
$10M
Series E
$60M
Debt
$7.5M
Stock Offering
$72.4M
Share Placement
$25M
Series B (1999): $12.3M with participation from Stafford Capital Partners
Series C (2000): $50M led by Stafford Capital Partners, Moore Capital, and Sands Brothers Asset Management
Series D (2005): $10M supported by Zen Investments
Series E (2007): $60M featuring Zen Investments, Oxford Bioscience Partners, Novo Nordisk, MedImmune Ventures, and Merlin Nexus
Debt (2010): $7.5M, investors not publicly disclosed
Stock Issuance/Offering (2013): $72.4M, investors not publicly disclosed
Share Placement (2021): $25M, investors not publicly disclosed
Key Investors in Xencor
Moore Capital
Moore Capital, LLC is committed to maximizing the value of our private equity investments as well as helping our partners achieve optimum success through a commitment to hard work, professional service, and confidentiality.
Oxford Bioscience Partners
Oxford Bioscience Partners is an international venture capital firm specializing in life science technology based investments, with offices in Boston, Massachusetts and Seoul, Korea.
MedImmune Ventures
MedImmune Ventures is the venture capital arm of a major biopharmaceutical entity, focusing on strategic investments in innovative companies that align with its broader therapeutic research goals.
What's next for Xencor?
Looking ahead, Xencor is poised to leverage its recent capital injection to accelerate its clinical trial programs and expand its therapeutic reach. The strategic focus remains on the maturation of its XmAb-based pipeline, which serves as the cornerstone of its long-term growth strategy. As the company transitions through its current lifecycle stage, the emphasis will likely shift toward achieving key regulatory milestones and potentially expanding its collaborative footprint with global pharmaceutical partners. The integration of this latest financing ensures that Xencor maintains the operational agility required to sustain its competitive advantage in the rapidly evolving field of biologic medicine.
See full Xencor company page
